Niclosamide - Hyundai Bioscience
Alternative Names: CP-COV03; Niclosamide dehydrotalcite-Hyundai Bioscience; Poly-COV01; XaftyLatest Information Update: 17 Feb 2025
At a glance
- Originator Hyundai Bioscience
- Developer CNPharm; Hyundai Bioscience
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; NF-kappa B inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
- Preclinical Monkeypox
Most Recent Events
- 31 Jan 2025 Hyndai Bio plans a clinical trial of Niclosamide in Dengue in Vietnam (PO)
- 31 Jan 2025 Vietnam’s Central Ethics Committee approves Clinical Trial Protocol application for Niclosamide in Dengue
- 28 Jan 2025 No recent reports of development identified for research development in COVID-2019-infections in South Korea (Parenteral, Injection)